Ubiquinol, like coenzyme Q10, also known as ubiquinone, does not appear to cause any side effects when taken in recommended doses. Marketers of ubiquinol recommend it as a better alternative to ubiquinone for people over age 40. As with any supplement, consult your physician before starting a regimen. Ubiquinol dosage recommendation is generally 200 to 300 mg daily for an initial three weeks, then a 100-mg daily maintenance dose.
According to a clinical study conducted in Tyler, Tex., patients in the latter stages of congestive heart failure receiving ubiquinol experienced increases of up to 50 percent in their hearts' blood-pumping ability. At the commencement of the study, patients had a six-month life expectancy, but all those treated with ubiquinol progressed past the six-month stage.
The Japanese firm Kaneka, the exclusive ubiquinol manufacturer, states that the supplement increases "energy, stamina and general wellness." However, these statements were not evaluated or approved by the U.S. Food and Drug Administration, and no diagnosis, prevention, treatment or curing of any physical problem is intended, according to a Kaneka disclaimer.
Ubiquinol is the active antioxidant form of coenzyme Q10, protecting the cells of the body from the effects of free radicals. According to the National Institutes of Health, free radicals are molecules produced in the body's breakdown of food, or by environmental toxins. Causing cell damage, free radicals may be linked to cancer, cardiac and other ailments.
In a study conducted at the University of Toyko, researchers found that patients suffering from various types of liver disease, including cirrhosis, heptoma and hepatitis, had decreased levels of ubiquinol due to oxidative stress, although the levels of ubiquinone were not lessened. As ubiquinol is generally well tolerated, the implication is that supplementation may help those with liver ailments.
A study in Japan found that patients with Type 2 diabetes had approximately 75 percent less natural ubiquinol in their bodies than a control group without the disease. As in the liver disease study, oxidative stress also contributed to lower levels of ubiquinol and not lower levels of ubiquinone.
- National Center for Biotechnology Information: Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers
- Medical News Today: Clinical Trial Shows Ubiquinol Has Significant Effect On Patients With Congestive Heart Failure
- Biosynergy: Ubiquinol
- Kaneka QH: Ubiquinol
- Ablestock.com/AbleStock.com/Getty Images